{Reference Type}: Journal Article
{Title}: Single gene mutations and prognosis in limited-stage follicular lymphoma treated with radiation therapy.
{Author}: Hershenfeld SA;Tobin JWD;Shelton V;Calvente L;Lajkosz K;Liu T;Brodtkorb M;d'Amore FA;Ludvigsen M;Baetz T;LeBrun D;Johnson N;Crump M;Hong M;Kuruvilla J;Tremblay-LeMay R;MacManus M;Tsang R;Hodgson DC;Gandhi MK;Kridel R;
{Journal}: Br J Haematol
{Volume}: 0
{Issue}: 0
{Year}: 2024 Aug 7
{Factor}: 8.615
{DOI}: 10.1111/bjh.19698
{Abstract}: Radiotherapy is routinely used for management of limited-stage follicular lymphoma (FL), yet half of patients ultimately relapse. We hypothesized that the presence of specific gene mutations may predict outcomes. We performed targeted sequencing of a 69-gene panel in 117 limited-stage FL patients treated with radiotherapy and identified recurrently mutated genes. CREBBP was most frequently mutated, and mutated CREBBP was associated with inferior progression-free survival, though not after false discovery rate adjustment. This association failed to validate in an independent cohort. We conclude that recurrent gene mutations do not predict outcomes in this setting. Alternative biomarkers may offer better prognostic insight.